Cost-Effectiveness Analysis Conference
Cost-Effectiveness Analysis – Evidence, Economics, and Politics: Australia’s Experiment in Evidence-Based Medicine – December 15, 2006
Conference Details:
Friday, December 15, 2006
7:30 a.m. – 10:30 a.m. Pacific Time
St. Regis Hotel
125 Third Street
San Francisco, California 94103
EVENT WILL BE WEBCAST LIVE AT: http://www.visualwebcaster.com/event.asp?id=37022
Registration and Continental Breakfast: 7:30 a.m.
Panel Discussion: 8:00 a.m.
Australia's Medicare system provides universal, tax-financed coverage to all citizens. Since 1993, the system's Pharmaceutical Benefits Advisory Committee (PBAC), which serves to provide advice to the Government on which drugs should be listed on the national formulary, has been required to incorporate an explicit consideration of comparative effectiveness and cost effectiveness as a prerequisite for coverage. With U.S. policymakers searching for ways to rein in Medicare and Medicaid drug spending, the Australian experience assumes special relevance.
Join policy experts from Australia and the U.S. for a discussion of the promise and pitfalls of cost-effectiveness analysis, a subject already of intense interest to the U.S. Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS).
Moderator:
John R. Graham
Director, Health Care Studies, Pacific Research Institute, and former Director of Health & Pharmaceutical Policy Research at Canada’s Fraser Institute
Panelists:
Meryl Comer
Journalist and Caregiver
Ruth Lopert
Harkness Fellow in Health Care Policy, George Washington University and Principal Advisor, Pharmaceutical Policy Taskforce, Commonwealth Department of Health and Ageing, Canberra, Australia
"Pharmacoeconomics & drug subsidy in Australia"
Peter J. Pitts
Co-Founder & President, Center for Medicines in the Public Interest, and former FDA Associate Commissioner for External Relations
Sponsors:
Registration:
There is no registration fee for this conference.
View the report: